EUCRISA®

Drug Information Related Patent

Hold Company

ANACOR PHARMS INC

Dosage and Administration

OINTMENT;TOPICAL

Specification

Indication

EUCRISA® is indicated for topical treatment of mild to moderate atopic dermatitis in adults and in pediatric patients 3 months of age and older.

Use

Instructions for Use

API

CRISABOROLE

API Structure

We Supply

CRISABOROLE

Note:

In-house Standard
Facility GMP
CDE/DMF/USMF

null

Note:

null

Note:

null

Drug Patent

Patent No	Expiration Date
8039451	2029/6/29
8039451*PED	2029/12/29
8168614	2030/1/20
8168614*PED	2030/7/20
8501712	2027/2/16
8501712*PED	2027/8/16
9682092	2027/2/16
9682092*PED	2027/8/16

API Patent

Patent No	Expiration Date
8039451	2029/6/29
8039451*PED	2029/12/29
8168614	2030/1/20
8168614*PED	2030/7/20
8501712	2027/2/16
8501712*PED	2027/8/16
9682092	2027/2/16
9682092*PED	2027/8/16

Note: The patent information provided herein is derived solely from publicly available data in the FDA Orange Book (or other cited sources) and is presented for general informational purposes only. Actual patent status may vary based on jurisdictional rulings, regulatory extensions or other factors.

HOURS

Daily: 9.30 AM–6.00 PM
Sunday : 9.30 AM–1.00 PM
Holidays: Closed

INFORMATION

Tel:
E-mail:
Address:
WhatsAPP

Member of

CERTIFICATION